Kornimate/medical-research-clean huggingface dataset:
international prospective observational cohort study for optimal bowel resection extent and central radicality for colon cancer

Conditions: Colon Cancer

Summary: the t-rex study aims to clarify the actual status of metastatic lymph node (ln) distribution in colon cancer and provide reliable evidence regarding the optimal length of bowel resection and the extent of central lymph node dissection in colon cancer surgery.

in colon canser, the incidence of metastasis in the pericolic lymph nodes (lns) located along the bowel and marginal artery is high. the optimal extent of bowel resection is closely associated with how we define 'regional' pericolic lns, which should be resected because of the risk of metastasis. however, there are no standardised criteria for 'regional' lns in the pericolic area. to establish a consensus for the extent of bowel resection and appropriate central ln dissection, international prospective stdies focusing on the distribution of metastatic lns along the bowel and the primary feeding artery are conducted.

Eligibility criteria:
inclusion criteria: * histologically proven colon adenocarcinoma * pathological stage ⅰ, ⅱ or ⅲ * potentially curative surgery * informed consent for observational data collection exclusion criteria: * tis (mucosal cancer) * multiple colon cancers * all patients with preoperative adjuvant therapy

Keywords: colon cancer, lymph node, extent of bowel resection
amisulpride in schizophrenic patients

Conditions: Schizophrenia

Summary: primary purpose: * to find out how effective is long term treatment with amisulpride on the positive and negative symptoms in schizophrenic patients * to find out how safe is long term treatment with amisulpride in schizophrenic patients secondary purpose: * to find out how effective is long term treatment with amisulpride on the quality of life in schizophrenic patients * to find out how effective is long term treatment with amisulpride on the cognitive function in schizophrenic patients


Eligibility criteria:
inclusion criteria: * patients diagnosed as schizophrenia or schizophrenic disorder according to dsm-iv * patients who need new anti-psychotic drugs or need to change the medication due to aggravations of symptoms or recurrence exclusion criteria: * patients with positive symptoms in whom the disorder does not correspond to schizophrenic criteria. (e.g, schizoaffective disorder) * patients hypersensitive to the active ingredient or to other ingredients of the study drug * prolactin-dependant tumors, pituitary gland prolactinomas and breast cancer * pheochromocytoma or parkinson's disease * pregnancy or breast feeding * current or recently withdrawn from drug abuse or alcoholism * chronic renal failure and other internal or surgical disease which physician decides will be worsened by trial medication or that will affect the metabolism or effects of the trial medication * patients with previous histories and clinical improvement was not seen in spite of treatment with 2 anti-psychotics for over 8 weeks * slow heart rate of \<55bpm, low blood potassium level, congenital prolongation of the qt interval * current treatment with a drug likely to cause markedly slow heart rate(\<55bpm), low blood potassium level, slowing of intercardiac condition or prolongation of the qt interval the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
does nesiritide provide renal protection

Conditions: Renal Failure

Summary: this project evaluates whether nesiritide, human recombinant brain natriuretic peptide, confers renal protection during cardiovascular surgery by attenuating the inflammatory response.

this will be a randomized, prospective blinded pilot study comparing nesiritide to placebo in patients undergoing aortic arch, ascending aorta, aortic valve or mitral valve surgery with baseline gfr 30-90ml/min. patients were randomized to either placebo or nesiritide (administered prophylactically starting in the operating room prior to incision at 0.01 mcg/kg /minute with no bolus and continued for 48 hours).

Eligibility criteria:
inclusion criteria: * patients undergoing surgery on their aortic arch, ascending aorta, or having aortic valve or mitral valve surgery * baseline mdrd (modification of diet in renal disease) calculated gfr (glomerular filtration rate) 30-90 ml/min. * signed informed consent exclusion criteria: * age \ 80 * ejection fraction \<30%. * presence of endocarditis or other infection. * presence or anticipated use of an intra-aortic balloon pump. * history of an organ transplant. * history of an adverse reaction to nesiritide. * surgery performed without cardiopulmonary bypass. * receiving aprotinin * dopamine administered in doses \<5 mcg /kg min. * women of child bearing potential or pregnant or breastfeeding. * participation in any other investigational trial * jehovah witness * bleeding disorder * active endocarditis

Keywords: renal failure cardiopulmonary bypass
intraperitoneal instillation of levobupivacaine with morphine versus levobupivacaine with magnesium sulfate for postoperative analgesia

Conditions: Post Operative Pain

Summary: this is a prospective randomized study that included 60 patients and was divided into two equal groups of patients who were scheduled for lc, ages 18 and 60 years, both sexes, asa i-ii and bmi 19 - 39. group a received 30 ml levobupivacaine (0.25%) plus 3 mg morphine intraperitoneal at the site of surgery in the bed of the gallbladder via the navel port with the patient in a trendelenburg position, group b received 30 ml levobupivacaine (0.25%) plus 50 mg/kg magnesium sulfate in the same pattern as in the a group.


Eligibility criteria:
inclusion criteria: * patients who were scheduled for l.c, * ages 18 and 60 years * asa i-ii and * bmi 19 - 39 exclusion criteria: * patients with hepatic or renal dysfunction * use of opioids 24 hrs prior to the study * treatment with steroids prior to surgery * drug or alcohol abuse, allergy to any of the study drugs * chronic pain syndrome as a result of neurological disease
efficacy and safety of endoscopic variceal ligation (evl) versus evl plus non-selective b-blockers (nsbb) for prevention of variceal rebleed and non-bleed related complications in patients with advanced cirrhosis

Conditions: Advanced Cirrhosis

Summary: the patients will be randomized into two groups 1. endoscopic variceal ligation with non selective beta blocker 2. placebo with endoscopic variceal ligation


Eligibility criteria:
inclusion criteria: * patients between 18 and 80 years old. * clinical criteria and/or analytical, ultrasound and/or liver biopsy consistent with the diagnosis of liver cirrhosis. * endoscopic diagnosis of esophageal variceal bleeding within 5 days prior to study inclusion. * written informed consent to participate in the study. * child c status, ctp \>10 exclusion criteria: * pregnancy or lactation * serum creatinine \> 2 mg/dl * bleeding due to gastric varices. * active infection or recent infection \< 2 weeks * presence of hepatocellular carcinoma or portal vein thrombosis * active alcoholism * pregnancy * hiv infection * severe heart, respiratory or contraindications for beta blockers(severe chronic obstructive pulmonary disease, severe asthma, severe insulin-dependent diabetes mellitus, brady arrhythmia) * not giving consent
interest of new mri sequences after embolization of brain arteriovenous malformations

Conditions: Brain Arteriovenous Malformations

Summary: in previous studies exploring specific sequences of mri (susceptibility weighted imaging (swi) and arterial spin labeling (asl)), the investigators have shown the great sensibility of these mri sequences to detect arteriovenous shunts, compared to angiography imaging (static or dynamic). this prospective study aims to compare multisequence mri to brain arteriography imaging in patients undergoing brain arteriovenous malformations embolization.

cerebral arteriovenous malformations are treated to eliminate the potential risk of haemorrhage. there are three possible treatment modalities: surgery, radiosurgery or embolisation. complete exclusion of the arteriovenous malformation is a prerequisite for confirming that there is no residual risk of haemorrhage. after treatment, arteriography is the gold standard for confirming this exclusion. the absence of early opacification of the venous drainage is considered a sign of cure. several arteriographic aspects are possible after treatment by embolisation: * arteriography may be strictly normal (no abnormalities). * the persistence of early venous opacification (presence of arterialised blood) indicates the persistence of a residual avm. * other vascular anomalies without early venous drainage may be present: dysplastic vessels (irregular shape, "corkscrew" appearance) ; capillary blush in the embolisation bed (hyperaemia) ; other: slow flow, slow filling, or widening of afferent arteries. our previous studies exploring the use of specific mri sequences, in magnetic susceptibility (swi), arterial spin labelling (asl) and angiography (static or dynamic) sequences, have enabled us to demonstrate the very high sensitivity of these sequences for detecting an arteriovenous shunt, whether native (when the avm is discovered) or residual after treatment. we would like to carry out a prospective study to compare cerebral arteriography and mri (multi-sequence) in patients treated by embolisation for cerebral arteriovenous malformation.

Eligibility criteria:
inclusion criteria: * patient ≥ 18 years old * with brain arteriovenous malformations * embolization treatment scheduled exclusion criteria: * patient's refusal to participate in the study * contraindication to undergo mri examination * patient under legal protection
the study about the efficacy of oral limaprost after surgery for cervical myelopathy

Conditions: Cervical Myelopathy

Summary: the limaprost alfadex can improve the surgical outcomes in patients with cervical myelopathy.


Eligibility criteria:
inclusion criteria: * older than 20 years old * compressive cervical myelopathy, confirmed by mri, including c1-c2 instability, ossification of posterior longitudinal ligament * plan to undergo cervical surgery for myelopathy * joa score less than 15 points * signed informed consent of patient or legal guardian exclusion criteria: * infection or malignancy * taking limaprost before surgery * pregnancy or expected to be pregnant or breast feeding * severe cardiovascular, pulmonary, renal disease or distress, brain pathology * any related coagulopathy * any drug to cause bleeding tendency * severe pain from other disease * any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study * patient cannot follow study protocol, for any reason

Keywords: limaprost alfadex cervical myelopathy surgery
association between the results of specific genetic tests and the efficacy of targeted therapies in patients

Conditions: Non-small Cell Lung Cancer

Summary: our study aimed to evaluate the correlation between test reagent specific gene test results and the efficacy of relevant targeted drugs in patients with non-small cell lung cancer, and to support the continued registration of test reagents.


Eligibility criteria:
inclusion criteria: * 1)≥18，advanced non-small cell lung cancer confirmed by histopathology, and were previously or currently treated with gefitinib tablets (as the first-line treatment) or osimertinib (first-generation tki resistance treatment) or crizotinib capsules monotherapy were evaluated for efficacy. * 2) able to provide ffpe samples with a storage life of 5 years: large specimen 5 pieces in each case; 10 puncture specimens in each case exclusion criteria: * 1) pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells \>20%); * 2) combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs; * 3) maintenance treatment when the disease does not progress after other anti-tumor treatments.
photodynamic diagnosis for malignant brain glioma with 5-aminolevulinic acid（5-ala）

Conditions: 5-aminolevulinic Acid; Malignant Glioma of Brain

Summary: this trial is an open-label, multicenter, phase iii clinical study，conducted in patients with newly diagnosed or recurrent malignant high-grade (who grades 3\~4) glioma, to evaluate the efficacy and safety of a single oral dose of 5-aminolevulinic acid (5-ala) oral solution powder for fluorescence-guided tumor resection and photodynamic diagnosis.


Eligibility criteria:
inclusion criteria: * patient's written informed consent * age 18-75 years * radiological suspicion of a malignant glioma * indication for surgical tumour resection * karnofsky performance status (kps) ≥ 70 exclusion criteria: * tumor located in the basal ganglia, thalamus, cerebellum, or brainstem * porphyria, hypersensitivity to porphyrins，history of cutaneous photosensitivity or photosensitive skin diseases； * known hypersensitivity to the test drug ingredients * any other condition that, in the opinion of the investigator, makes participation in the trial inappropriate;
ace2 chewing gum on sars-cov-2 viral load (covid 19)

Conditions: SARS-CoV-2

Summary: a randomized double-blind, placebo controlled clinical trial of the safety, tolerability, and antiviral activity of angiotensin-converting enzyme 2 (ace2) chewing gum over a 3-day period in non-hospitalized subjects with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide informed consent prior to initiation of study procedures. 2. stated willingness to comply with all study procedures and availability for the duration of the study. 3. male or female, aged 18 years to 65 years. 4. had a positive pcr or antigen test for sars-cov-2 within 72 hours of enrollment. 5. in the opinion of the investigator, has the ability to comply with study procedures including chewing the study products (gum). 6. stated willingness to refrain from brushing, eating or using any oral health care products, including mouth rinses at least one hour prior to first saliva sample. 7. stated willingness to abstain from eating mints or other chewing gums during the duration of the study. 8. stated willingness to abstain from using mouth rinse/gargling solutions at the time of enrollment and for the duration of the study. 9. stated willingness to use an acceptable method of birth control throughout duration of the study. acceptable methods include hormonal contraceptives, barrier methods, abstinence, or other effective methods approved by the pi. 10. stated ability and willingness to store saliva samples at approximately 40° f for 3 days. exclusion criteria: 1. individuals receiving antiviral medications that are thought to be active against sars-cov-2 in the opinion of the investigator. 2. individuals receiving oral or injectable antimicrobial medications (antibacterial, antiviral, antibiotics, including hydroxychloroquine) at time of enrollment. 3. currently undergoing cancer treatment. 4. pregnant or breastfeeding women. 5. participation in any other clinical trial within the past 14 days that used an investigational drug product. 6. admitted to the hospital or other medical facility or in the opinion of the investigator expected to require admission to a medical facility for the duration of the study. 7. taking chronic immunosuppressive medications at time of enrollment, defined as immunomodulatory agents or a prednisolone dose greater than 10 mg a day. 8. uncontrolled hypertension, defined as ≥160 mmhg systolic or ≥100 mmhg diastolic. 9. allergy/hypersensitivity to lettuce, gelatin (plant based), stevia, or unwillingness to consume genetically modified plant material.
effect of short foot exercise in treatment of patients with patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: purposes of the study to investigate the effect of adding short foot exercise on patellofemoral pain syndrome on knee pain, function, balance and abductors, quadriceps muscle strength.


Eligibility criteria:
inclusion criteria: * patients diagnosed as pfps * pain elicited at least by two of the following four tests; (i) isometric muscle contraction with slight bent knee,(ii) palpation of the patellofemoral joint line, (iii) patellar compression against the femoral bone (iv) active resisted knee extension. * psychological and mentally stable * no previous knee surgery, except for diagnostic arthroscopy. * no current knee pathologies (e.g. osteoarthritis) * navicular drop test more than 10 mm which indicated pronated foot exclusion criteria: - subjects will be excluded if they don't meet the inclusion criteria.

Keywords: short foot exercise patellofemoral pain syndrome
body weight and carb metabolism

Conditions: Exercise Metabolism

Summary: whilst theoretically, body size should influence the capacity for intestinal carbohydrate absorption and thus exogenous oxidation rates during exercise, there is currently little empirical evidence to support this hypothesis. accordingly, current nutrition guidelines for carbohydrate intake during exercise do not take body mass into account. therefore, there is a need to establish whether body mass is related to exogenous carbohydrate oxidation rates during exercise. if such a relationship is established, this would lay the foundation to revise the current sports nutrition guidelines regarding carbohydrate intake during exercise. the aims of this study are, therefore, to: 1) establish whether larger individuals display higher rates of exogenous carbohydrate oxidation than smaller individuals; and 2) establish if such a difference can be explained by the higher absolute exercise intensity, and thus the energy demand of exercise. it is hypothesised that larger individuals will demonstrate higher exogenous carbohydrate oxidation rates than smaller individuals, and that this difference will be partly (but not completely) diminished when the absolute intensity of exercise is matched.


Eligibility criteria:
inclusion criteria: * able to cycle continuously for 2 hours at a moderate intensity * vo2max of between 40-75 ml/kg/min * fat-mass index (determined by dual energy x-ray absorptiometry) \< 5.5 kg·m-2 exclusion criteria: * diagnosed disorders of the gastrointestinal tract (e.g. crohn's, colitis etc.) * people following a low-carbohydrate, high-fat diet * pregnant or lactating * diagnosed cardiovascular disease * possible symptoms of cardiovascular disease * diagnosis of diabetes of any type * hypercholesterolaemia (total cholesterol ≥ 6.2 mmol/l * hypertension (systolic blood pressure ≥140 mmhg or diastolic blood pressure ≥90 mmhg) * current smoker * family history of coronary artery disease (first-degree relative \<60 years) * prevalence of vascular disease * autonomic neuropathy * kidney disease * diagnosed pulmonary disease (e.g. chronic obstructive pulmonary disease, asthma, interstitial lung disease or cystic fibrosis) * blood borne disease or infection * osteoporosis * osteoarthritis * blood clotting disorders * food intolerances/allergies (these may not specifically exclude you- please talk to the investigator) * sensitivity or allergy to anaesthetic
lymphocyte counts in immune thrombocytopenic purpura

Conditions: Thrombocytopenic Purpura

Summary: * immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number (cooper n et al 2006) * recent studies have demonstrated that the pathogenesis of itp envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( cooper n et al 2006) ( gern sheimer t 2009 )

immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number ( cooper n et all 2006) platelet surface membrane proteins become antigenic for unknown reasons, leading to stimulation of the immune system, auto antibodies production and platelet destruction ( gasbarrini a et all 2000) it is associated with the production of auto antibodies directed against platelet glycoprotein complex 2b/3a and/or 1b/1x , resulting in accelerated destruction of platelets by the reticular endothelial system via the activity of fcc receptor bearing phagocytic cells ( provan \& newland et al 2002) recent studies have demonstrated that the pathogenesis of itp envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( cooper n et al 2006) ( gern sheimer t 2009) there are many phases of the disease: 1. newly diagnosed itp : for all cases at diagnosis. 2. persistent itp: for patients with itp between 3 to 12 months. 3. chronic itp: for patients with itp lasting more than one year ( blood journal 2009). * although lymphocytopenia is a commonly reported feature of many chronic autoimmune disorders, differential white cell counts at presentation have seldom been evaluated as predictors for development of chronic itp ( deel md et al 2013) (ahmed et al 2010)

Eligibility criteria:
inclusion criteria: * newly diagnosed cases of primary itp , adults and children. exclusion criteria: * cases of secondary itp
telephone intervention in patients with acute coronary syndrome (acs) and diabetes

Conditions: Type 2 Diabetes Mellitus; Acute Coronary Syndrome

Summary: hypothesis to investigate whether telephone counselling by nurse educator between clinic visits with particular emphasis on adherence to medications and lifestyle modification in patients with coronary heart disease and diabetes will reduce mortality and hospitalisation rates due to cardiovascular events compared to usual clinic-based care.

study-design a 2-year multicentre, randomised controlled open study involving 5 ha hospitals in hong kong. subjects and method one thousand two hundred and sixteen patients admitted to hospital with principle diagnosis of coronary heart disease and known or newly confirmed diabetes on oral glucose tolerance test will be enrolled. patients in the intervention arm (n=608) will receive telephone intervention between clinic visits by diabetes nurse educator using structured counselling tools with particular emphasis on adherence to lifestyle modification and medications as well as self-monitoring of blood glucose, blood pressure and body weight. patients in control group (n=608) will not receive telephone intervention. both groups will be followed up by their usual medical teams in their hospitals upon discharge. clinical endpoints primary endpoint is the composite of death and/or cardiovascular related hospitalisations. secondary endpoints include hospitalisations due to cardiovascular events, number of hospital admissions, total number of days of hospital stay and attendance at the accident and emergency department.

Eligibility criteria:
inclusion criteria: * patients admitted to the 5 ha hospitals with principle diagnosis of chd, age 45 years for male and 55 for female * presence of diabetes according to the 1998 who criteria and no history of unprovoked ketosis and not requiring continuous insulin treatment within 1 year of diagnosis exclusion criteria: * patients with terminal malignancy or other life-threatening diseases with less than 3-month expected survival * telephone contact not available * patients with a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study * patients who speak non-cantonese dialect or different language or have conditions that prevent effective communications e.g. patients who are deaf and mute * patients who live in nursing home with supervised treatment * patients who have participated in another intervention study during the last 1 month and who are enrolled in any intervention studies.

Keywords: drug compliance lifestyle modification